
Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

Joining forces for mRNA breakthrough
Global biotech Dyadic International Inc. and French bYoRNA SAS officially sealed a strategic partnership on the 26th of September aimed at advancing...

German company aims for the first EU approval for cell-cultured meat
The Cultivated B (Heidelberg, Germany) is the first company in the world to pre-register a partially cell-based meat product with the European Food...

CPHI: Trends shaping pharma's path
Despite challenges such as funding slowdowns for biotechs and concerns about high inflation, the industry remains cautiously optimistic,...

microRNA could offer a safe target in atherosclerosis
The researcher demonstrateded that targeting of miR-206-3p with an experimental compound safely reversed the onset of atherosclerosis in a...

Synerkine Pharma BV secures EUR 12.1m in Series A extension
The Series A extension was led by Flerie with participation of existing investor Thuja Capital and new investors InnovationQuarter Capital and...

Repairing MS-caused damage with stem cells
Results of a investigator-initiated Phase I stem cell therapy trial have shown promise as a treatment for progressive multiple sclerosis. The...